Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 12;32(48):6356-9.
doi: 10.1016/j.vaccine.2014.09.033. Epub 2014 Sep 22.

HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011

Elissa Meites  1 , Lauri E Markowitz  2 , Gabriela Paz-Bailey  3 , Alexandra M Oster  4 ; NHBS Study Group
Collaborators, Affiliations

HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011

Elissa Meites et al. Vaccine. .

Abstract

Men who have sex with men (MSM) are at high risk for disease associated with human papillomavirus (HPV). In late 2011, HPV vaccine was recommended for males through age 21 and MSM through age 26. Using data from the 2011 National HIV Behavioral Surveillance System, we assessed self-reported HPV vaccine uptake among MSM, using multivariate analysis to calculate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Among 3221 MSM aged 18-26, 157 (4.9%) reported ≥1 vaccine dose. Uptake was higher among men who visited a healthcare provider (aPR 2.3, CI: 1.2-4.2), disclosed same-sex sexual attraction/behavior to a provider (aPR 2.1, CI: 1.3-3.3), reported a positive HIV test (aPR 2.2, CI: 1.5-3.2), or received hepatitis vaccine (aPR 3.9, CI: 2.4-6.4). Of 3064 unvaccinated MSM, 2326 (75.9%) had visited a healthcare provider within 1 year. These national data on HPV vaccine uptake among MSM provide a baseline as vaccination recommendations are implemented.

Keywords: Human papillomavirus (HPV); Men who have sex with men (MSM); Vaccine uptake.

PubMed Disclaimer

Conflict of interest statement

Disclosures: No conflicts of interest were declared. All authors materially participated in the research and article preparation, and have approved the final article. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

References

    1. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012 May;13(5):487–500. - PubMed
    1. Llata E, Stenger M, Bernstein K, Guerry S, Kerani R, Pugsley R, et al. Prevalence of genital warts among sexually transmitted disease clinic patients – Sexually Transmitted Disease Surveillance Network, United States, January 2010 to December 2011. Sex Transm Dis. 2014 Feb;41(2):89–93. - PMC - PubMed
    1. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012 Apr;54(7):1026–34. - PMC - PubMed
    1. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011 Oct;365(17):1576–85. - PubMed
    1. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males – Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011 Dec;60(50):1705–8. - PubMed

Publication types

Substances